Breast cancer remains one of the leading causes of cancer-related mortality worldwide, with its complexity largely attributed to diverse genetic and metabolic adaptations that cancer cells leverage for survival and proliferation. At the heart of these adaptations lies altered lipid metabolism, a hallmark of cancer responsible for supplying energy and biosynthetic precursors essential for tumor expansion. The researchers focused on CYB561, a transmembrane protein traditionally implicated in electron transport and redox biology, hypothesizing its possible involvement in metabolic reprogramming within breast cancer cells.

Their comprehensive analyses revealed that CYB561 expression is markedly upregulated in breast cancer tissues compared to normal mammary epithelium. Using patient-derived samples and breast cancer cell lines, the team demonstrated that heightened CYB561 levels correlate strongly with increased lipid accumulation within cancer cells, signifying its role in enhancing lipogenesis. This enhanced lipid synthesis fuels membrane biogenesis and energy requirements, facilitating rapid tumor proliferation and survival under hostile microenvironmental stresses.

Delving deeper, the investigators unraveled the molecular pathways through which CYB561 exerts its oncogenic influence. Central to this process is the activation of the unfolded protein response (UPR) pathway, particularly the branch mediated by IRE1 (inositol-requiring enzyme 1) and its downstream transcription factor XBP1. The study showed that CYB561 activation potentiates the IRE1-XBP1 axis, which in turn upregulates SREBF1 (sterol regulatory element-binding transcription factor 1), a master regulator of lipogenic genes. This cascade results in amplified expression of enzymes critical for de novo fatty acid synthesis, reinforcing the lipid anabolic state essential for breast cancer cell growth.

Simultaneously, CYB561 also engages the focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK) signaling pathway. This axis is well-recognized for its roles in cell migration, survival, and proliferation. By stimulating FAK-ERK signaling, CYB561 augments metastatic potential and tumor aggressiveness. This dual modulation of metabolic and signaling pathways by CYB561 effectively cements its status as a multifaceted promoter of breast cancer progression.

The researchers employed a series of in vitro and in vivo experiments to validate the functional significance of CYB561 in breast cancer. Silencing CYB561 expression resulted in impaired lipid synthesis capacity, reduced proliferation rates, and diminished invasiveness of breast cancer cells. Murine xenograft models further showed that tumors with suppressed CYB561 levels exhibited slower growth kinetics and decreased metastatic dissemination, underscoring the therapeutic promise of targeting CYB561.

Importantly, the study also illuminated the interplay between CYB561-driven metabolic reprogramming and cellular stress adaptation. By enhancing the IRE1-XBP1 pathway, CYB561 not only boosts lipogenesis but also mitigates endoplasmic reticulum (ER) stress, a condition detrimental to tumor survival. This adaptive advantage allows breast cancer cells to thrive despite the high biosynthetic demand and environmental challenges, emphasizing the resilience imparted by CYB561.

Given the dual role of CYB561 in lipid metabolism and oncogenic signaling, the protein emerges as a potential biomarker for breast cancer aggressiveness and a novel drug target. Therapeutic strategies aimed at inhibiting CYB561 could disrupt the metabolic equilibrium of breast cancer cells, rendering them more susceptible to existing treatments and curbing disease progression.

Moreover, the elucidation of CYB561’s involvement in these pathways opens avenues for combinational therapies targeting multiple aspects of tumor biology simultaneously. For instance, coupling CYB561 inhibitors with agents that induce ER stress or block FAK-ERK signaling might yield synergistic effects, amplifying anti-tumor efficacy.

While this study provides compelling mechanistic insights, the authors acknowledge that further investigations are necessary to explore CYB561’s roles across different breast cancer subtypes and stages. Additionally, the development of specific and potent CYB561 inhibitors will be crucial for translating these findings into clinical interventions.

The revelation that a single oncoprotein such as CYB561 can orchestrate both metabolic and signaling cascades to drive breast cancer progression underscores the complexity of tumor biology. This multifaceted influence exemplifies the evolving perspective in oncology, where cancer metabolism and signal transduction are intertwined and co-dependent, necessitating integrated research approaches.

In summary, the identification of CYB561 as a central modulator bridging the IRE1-XBP1-SREBF1 lipogenic pathway and the FAK-ERK signaling axis offers a paradigm shift in understanding breast cancer pathogenesis. Targeting this nexus could pave the way for innovative and more effective therapies, potentially transforming the clinical landscape for patients afflicted with breast cancer.

As the fight against breast cancer continues, studies such as this reaffirm the critical importance of dissecting molecular mechanisms with precision. By unveiling novel targets like CYB561, the scientific community moves closer to devising personalized medicine strategies that could significantly improve patient prognosis and quality of life.

The convergence of lipid metabolism and signal transduction in the tumor microenvironment, as exemplified by CYB561, also highlights the adaptability of cancer cells in co-opting normal cellular machinery for malignant advantage. These insights not only enhance our theoretical understanding but also inspire next-generation therapeutic design.

Ultimately, the integration of metabolic and signaling pathway targeting heralds a new era in cancer therapy, where disrupting the core vulnerabilities of cancer cells can achieve enduring remission. The discovery of CYB561’s pivotal role in breast cancer progression represents a vital step toward this ambitious goal.

Subject of Research: The role of oncoprotein CYB561 in breast cancer lipogenesis and progression through metabolic and signaling pathways.

Article Title: Oncoprotein CYB561, acting in IRE1-XBP1-SREBF1 and FAK-ERK pathway, promotes breast cancer lipogenesis and progression.

Article References: Yang, X., Tao, Y., Xu, Y. et al. Oncoprotein CYB561, acting in IRE1-XBP1-SREBF1 and FAK-ERK pathway, promotes breast cancer lipogenesis and progression. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03101-2

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03101-2

Breast cancer pathogenesis is notoriously driven by complex signaling networks that promote unchecked cellular proliferation and survival. Among these, the phosphatase and tensin homolog (PTEN) plays a pivotal tumor suppressor role by antagonizing the PI3K/AKT pathway, a critical axis involved in oncogenic signaling. Loss or downregulation of PTEN is frequently correlated with an aggressive tumor phenotype and resistance to conventional therapies, making it an attractive target for molecular intervention.

The study, spearheaded by Ashraf, M., Aftab, U., and Akhtar, T., elucidates how glycyrrhizin facilitates the upregulation of PTEN expression in breast cancer cells. Using a combination of molecular biology techniques, including quantitative PCR, Western blot analysis, and immunocytochemistry, the research team systematically demonstrated that glycyrrhizin administration reinstates PTEN levels that were markedly reduced in malignant breast tissue samples and cell lines.

This restoration of PTEN exerts a downstream inhibitory effect on the oncogenic PI3K/AKT signaling cascade. Subsequent assays revealed a significant decrease in phosphorylated AKT, a hallmark indicator of pathway activation, suggesting that glycyrrhizin effectively dampens oncogenic signaling that fuels tumor growth and metastasis. These mechanistic insights are critical, as they establish a direct biochemical link between glycyrrhizin and tumor suppressor pathways that have been previously exploited with limited success.

Intriguingly, beyond PTEN modulation, glycyrrhizin appeared to engage multiple cellular processes that augment its anticancer efficacy. The research highlighted glycyrrhizin’s ability to induce apoptosis and cell cycle arrest. Flow cytometric analyses identified a substantial increase in the percentage of apoptotic cells upon glycyrrhizin treatment, coupled with an accumulation of cells in the G1 phase, indicating a halt in cell cycle progression. These cytostatic and cytotoxic effects collectively impede the proliferative advantage of cancer cells.

Importantly, glycyrrhizin’s influence was not restricted to in vitro models. The authors extended their investigations to murine xenograft models bearing human breast cancer tumors. Consistent with cellular findings, glycyrrhizin-treated mice exhibited marked tumor growth suppression without significant adverse effects, underscoring its therapeutic potential and favorable safety profile.

One of the remarkable attributes of glycyrrhizin is its origin from licorice root, a substance with a long-standing history in traditional medicine for various ailments. This natural compound’s transition from anecdotal use to a scientifically validated anticancer agent exemplifies the increasing appreciation for phytochemicals in modern oncology. It brings forth the prospect of exploring integrative strategies where conventional chemotherapeutics might be augmented with such bioactive compounds.

The research also shed light on the molecular intricacies behind glycyrrhizin’s effect on PTEN regulation. Epigenetic analyses indicated that glycyrrhizin mitigates promoter methylation of the PTEN gene. This epigenetic remodeling promotes transcriptional activation, enabling the restoration of PTEN protein synthesis. This finding is particularly compelling because aberrant DNA methylation is a common mechanism by which tumor suppressor genes are silenced in cancerous cells.

Beyond these molecular ramifications, glycyrrhizin’s impact on the tumor microenvironment was another layer dissected in the study. Experiments demonstrated reduced markers of angiogenesis, such as vascular endothelial growth factor (VEGF), following glycyrrhizin treatment. Since angiogenesis is crucial for tumor sustenance and metastasis, the anti-angiogenic properties of glycyrrhizin add to its multifaceted anticancer action.

The study also ventured into the modulation of immune-related pathways. Glycyrrhizin appeared to recalibrate cytokine profiles within the tumor milieu, potentially enhancing antitumor immune surveillance and response. Such immunomodulatory effects could complement its direct inhibitory actions on cancer cells, offering a dual-pronged strategy against tumor development.

Clinically, these revelations open new avenues for breast cancer management. Given the high prevalence of PTEN loss and PI3K/AKT pathway hyperactivation in breast cancer patients, glycyrrhizin could serve as an adjuvant treatment, possibly improving outcomes where existing therapies fail due to resistance mechanisms. Furthermore, its natural origin and tolerability profile may translate into better patient compliance and fewer side effects.

However, the translation of glycyrrhizin from bench to bedside necessitates rigorous clinical trials to validate efficacy, optimal dosing, and potential interactions with standard treatments. The study by Ashraf and colleagues lays a robust foundation but also signals the need for further investigation into pharmacokinetics, long-term outcomes, and combinatorial regimens.

Moreover, the specificity of glycyrrhizin’s action raises intriguing questions. Does glycyrrhizin preferentially affect cancer cells over normal tissue? What are the off-target effects, if any? Addressing these concerns will be pivotal in defining its clinical application spectrum and safety margins.

The potential impact of this research resounds beyond breast cancer alone. Since PTEN and PI3K/AKT pathways are dysregulated in various cancers, glycyrrhizin or its derivatives might find utility across oncological disciplines, prompting a wider evaluation of this natural compound’s anticancer repertoire.

This research exemplifies how revisiting traditional compounds through the lens of molecular oncology can yield transformative insights. As the fight against cancer intensifies, integrating natural agents like glycyrrhizin could complement existing modalities, offering hope for more effective, less toxic therapies.

As science continues to unravel the molecular complexities of cancer, studies such as this underscore the importance of innovative, multidisciplinary approaches. Glycyrrhizin’s journey from licorice root to a promising antitumor agent marks a significant milestone in oncological research and patient care.

Future research trajectories could explore structural analogs of glycyrrhizin with enhanced bioavailability and potency. Additionally, elucidating its synergistic potential with other targeted inhibitors may improve therapeutic regimens.

Ultimately, the discovery that glycyrrhizin upregulates PTEN and suppresses oncogenic signaling navigates a new pathway toward controlling breast cancer’s relentless progression. It stands as a beacon of hope in the ongoing quest to harness nature’s pharmacopeia for curing cancer.

Subject of Research: Breast Cancer and the Molecular Effects of Glycyrrhizin on Tumor Suppressor PTEN and Oncogenic Signaling Pathways

Article Title: Glycyrrhizin upregulates PTEN and suppresses oncogenic signaling in breast cancer

Article References:
Ashraf, M., Aftab, U., Akhtar, T. et al. Glycyrrhizin upregulates PTEN and suppresses oncogenic signaling in breast cancer. Med Oncol 43, 124 (2026). https://doi.org/10.1007/s12032-026-03268-9

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-026-03268-9

Breast cancer remains the second leading cause of cancer-related mortality among American women, with metastasis accounting for over 90% of fatalities. Despite advancements in therapeutic regimens, the complete landscape of molecular drivers fueling breast cancer dissemination and resistance to treatments has remained elusive. Nelson’s team has now made a pivotal contribution toward filling this critical knowledge gap by spotlighting the role of cholesterol metabolites in modulating tumor-immune interactions.

Building on prior epidemiological associations linking elevated cholesterol levels with adverse breast cancer outcomes, Nelson’s laboratory utilized sophisticated preclinical animal models to focus on a specific cholesterol derivative: 27-hydroxycholesterol (27HC). Their research delineates how 27HC orchestrates immune evasion mechanisms by modulating neutrophil behavior, fundamentally altering the immune system’s capacity to target and eliminate cancer cells. Neutrophils, a frontline immune cell subset, respond to 27HC by secreting extracellular vesicles (EVs), small membrane-bound particles that serve as potent intercellular communicators.

Delving deeper into the mechanistic underpinnings, the team uncovered that these neutrophil-derived EVs convey pro-tumorigenic signals to breast cancer cells, effectively reprogramming them toward a more aggressive phenotype. This communication axis actively promotes epithelial-mesenchymal transition (EMT), a cellular process where epithelial tumor cells acquire migratory, invasive, and stem-like characteristics, thereby enhancing metastatic potential and chemotherapy resistance. Such findings delineate how 27HC facilitates a microenvironment conducive to cancer progression by hijacking immune cell communication modalities.

The study, recently published in Cancer Letters, marks a significant advancement in our understanding of tumor-immune system crosstalk mediated through extracellular vesicles. First author Natalia Krawczynska elaborates on their discovery: “27HC instructs neutrophils to customize the cargo of secreted EVs, which subsequently interact with cancer cells, inducing transcriptional and phenotypic changes that endow them with stemness and chemoresistance.” These insights elevate the biological importance of EVs as not merely cellular debris but as sophisticated vehicles orchestrating cancer dynamics.

Erik Nelson emphasizes the translational potential of these findings: “By interrupting this neutrophil EV messaging system, we can sensitize metastatic breast cancer cells to existing chemotherapies, potentially improving patient outcomes.” This concept heralds a paradigm shift, suggesting that therapeutic strategies targeting EV-mediated communication could complement and potentiate current treatment modalities.

Looking forward, Nelson’s team aims to pioneer novel intervention strategies that disrupt the early-stage dialogue between neutrophil EVs and cancer cells. Early therapeutic blockade of this axis could reduce the incidence of metastatic spread, which remains the principal cause of breast cancer lethality. The laboratory plans to pursue high-throughput screening of available pharmacological agents and collaborate with chemists to engineer new compounds capable of modulating EV biogenesis and cargo composition.

Furthermore, the lab is exploring the influence of diet, pharmacological agents, and host biological factors on the neutrophil EV signaling network. Understanding how lifestyle and systemic variables impact this microenvironmental conversation could reveal adjunctive modalities to prevent cancer progression. The researchers also hypothesize that neutrophil EVs might exert multifaceted effects on other stromal and immune constituents within the tumor microenvironment, propagating a complex ‘telephone game’ of signals that collectively drive malignancy.

This multi-pronged research endeavor leverages the interdisciplinary expertise converging at the Cancer Center at Illinois, uniting biologists, bioengineers, chemists, and computational scientists in pursuit of comprehensive elucidation and therapeutic targeting of EV-mediated communication. The center’s collaborative ethos and technological resources position it uniquely to translate these molecular insights into clinical innovations.

In addition to preclinical exploration, Nelson’s lab is setting the stage for clinical collaborations aimed at evaluating the prognostic potential of circulating neutrophil EVs in breast cancer patients. Monitoring EV profiles in patient blood samples could serve as an early biomarker for metastatic relapse, enabling preemptive intervention strategies tailored to individual disease trajectories and enhancing personalized medicine approaches.

Crucially, the team demonstrated that neutralizing the ‘message’ encoded by 27HC-exposed neutrophil EVs can reverse the malignant phenotype, restoring sensitivity to chemotherapy and reducing metastatic competency. This proof-of-concept establishes a tangible target for future drug development and clinical trials, highlighting the therapeutic viability of disrupting immune cell-tumor communication vectors.

The implications of this research extend beyond breast cancer, as EVs are emerging as universal mediators in various cancer types and immune-related diseases. These findings not only deepen our molecular understanding of cancer biology but also inspire a novel class of interventions harnessing the modulation of immune-derived extracellular vesicles to combat metastasis and therapeutic resistance.

Overall, Erik Nelson and his colleagues have unveiled a sophisticated molecular mechanism by which a cholesterol metabolite manipulates immune surveillance to exacerbate breast cancer progression. Their work bridges fundamental immunology, cancer biology, and translational research, providing a foundation for innovative strategies to undermine tumor resilience and improve patient prognosis in the ongoing battle against breast cancer.

Subject of Research: The molecular mechanisms by which cholesterol metabolites, particularly 27-hydroxycholesterol (27HC), influence neutrophil extracellular vesicle secretion and the subsequent promotion of epithelial-mesenchymal transition and stemness in breast cancer cells, leading to enhanced metastasis and chemotherapy resistance.

Article Title: Neutrophils exposed to a cholesterol metabolite secrete extracellular vesicles that promote epithelial-mesenchymal transition and stemness in breast cancer cells

News Publication Date: 28 October 2025

Web References:
https://www.sciencedirect.com/science/article/pii/S0304383525006779
http://dx.doi.org/10.1016/j.canlet.2025.218105

Keywords: Cancer, Breast cancer, Metastasis